Skip to main content
. 2021 Dec 10;9(12):e003645. doi: 10.1136/jitc-2021-003645

Figure 2.

Figure 2

Progression-free survival (PFS) per independent review (A) and long-term follow-up for overall survival (OS) (B) (patients receiving intravenous enadenotucirev plus paclitaxel). NA, not available.